Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kura Oncology
(NQ:
KURA
)
16.59
-1.16 (-6.56%)
Streaming Delayed Price
Updated: 3:46 PM EST, Nov 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kura Oncology
< Previous
1
2
3
4
Next >
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
October 14, 2024
Via
Benzinga
KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024
August 08, 2024
KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
July 17, 2024
Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.
Via
InvestorPlace
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
2 Incredible Growth Stocks to Buy Hand Over Fist
May 08, 2024
These two healthcare growth stocks could have a lot more room to run.
Via
The Motley Fool
Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6
March 06, 2024
Via
Investor Brand Network
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024
May 02, 2024
KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Kura Oncology: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Earnings Outlook For Kura Oncology
February 26, 2024
Via
Benzinga
Kura Oncology Inc. (NASDAQ: KURA) Near the Top of Equities by Percentage Gain on 1/24
January 24, 2024
Via
Investor Brand Network
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Kura Makes Good On Its $150 Million Infusion And Shoots Up Another 15%
January 30, 2024
The company just released promising results for its acute myeloid leukemia treatment.
Via
Investor's Business Daily
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 30, 2024
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Via
Benzinga
A Preview Of Kura Oncology's Earnings
November 01, 2023
Via
Benzinga
Analyst Expectations for Kura Oncology's Future
September 07, 2023
Via
Benzinga
Why Cancer-Drug Developer Kura Oncology Stock Is Up
January 30, 2024
Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all...
Via
Benzinga
General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday
January 30, 2024
U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Edges Lower; US Composite PMI Rises In January
January 24, 2024
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 24, 2024
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 24, 2024
Via
Benzinga
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
January 24, 2024
Latest surge in Kura Oncology shares with a $150 million private placement announcement. Cash runway extended into 2027.
Via
Benzinga
Textron Posts Upbeat Earnings, Joins ASML, Progressive And Other Big Stocks Moving Higher On Wednesday
January 24, 2024
U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Wednesday. Shares of Textron Inc. (NYSE: TXT) rose during Wednesday’s session following upbeat quarterly earnings.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why
January 24, 2024
Kura Oncology is still a week out from unveiling the results for an AML drug. But shares soared Wednesday.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 24, 2024
Via
Benzinga
Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst
December 22, 2023
Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatment for relapsed/refractory (r/r) NPM1-m acute myeloid leukemia...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 27, 2023
Via
Benzinga
Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients
October 18, 2023
Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is...
Via
Benzinga
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP® Technology
September 13, 2023
Allarity Therapeutics (NASDAQ: ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.